The interactions of novel mononuclear platinum-based complexes with DNA

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Cisplatin is a widely used chemotherapy drug that exerts its anti-tumor effects by forming DNA adducts, primarily at guanine residues, thereby inhibiting DNA replication and transcription.
• Significant challenges associated with cisplatin include dose-limiting toxicities and the development of drug resistance, necessitating the exploration of novel platinum-based analogs with improved therapeutic profiles.
• This study investigates three novel platinum-based compounds and one commercial compound, focusing on their biological properties as potential anticancer agents.

Purpose of the Study:

• To characterize the biological properties of three novel platinum-based compounds with varying cis-configured ligand groups.
• To compare the DNA adduct formation, sequence specificity, DNA unwinding, interstrand cross-linking, and cytotoxicity of these novel compounds against cisplatin.
• To evaluate the potential of these novel platinum compounds as improved anticancer agents.

Main Methods:

• Linear amplification reaction and capillary electrophoresis were used to quantify the sequence specificity of DNA adducts induced by the compounds on a telomeric repeat sequence DNA template.
• Denaturing and native agarose gel electrophoresis were employed to assess DNA interstrand cross-linking and unwinding efficiencies, respectively.
• Cytotoxicity was evaluated in HeLa cells using a colorimetric cell viability assay.

Main Results:

• All three novel platinum compounds induced DNA adduct formation at telomeric repeat sequences with distinct sequence specificity profiles compared to cisplatin.
• Two compounds, featuring the enantiomeric 1,2-diaminocyclohexane ligand (SS and RR-DACP), exhibited greater DNA unwinding capacity than cisplatin, although with slightly lower DNA cross-linking efficiencies.
• The RR-isomer demonstrated higher cytotoxicity in HeLa cells than cisplatin.

Conclusions:

• The novel platinum compounds exhibit distinct biological characteristics compared to cisplatin, including varied DNA adduct sequence specificity and enhanced DNA unwinding capabilities.
• The observed differences suggest these compounds may offer advantages over cisplatin in terms of mechanism of action and potentially therapeutic efficacy.
• These findings support further investigation of these compounds for the development of more effective chemotherapeutic drugs.